# Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Source: https://onco.cc/trials/nct05727904/  
OnCo record `nct05727904` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab in melanoma, run by Iovance Biotherapeutics, Inc., now recruiting.

## Summary

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. is a phase 3 interventional study registered as NCT05727904 by Iovance Biotherapeutics, Inc., with 670 participants planned, started 2023-03-30 and due to reach its primary completion in 2028-03-01. Interventions recorded: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period. Conditions listed: Metastatic Melanoma, Unresectable Melanoma, Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05727904
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma
- Sponsor: Iovance Biotherapeutics, Inc.
- Enrolled: 670

## Sources

- ClinicalTrials.gov NCT05727904: https://clinicaltrials.gov/study/NCT05727904

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Iovance Biotherapeutics](https://onco.cc/companies/iovance/)

---
JSON: https://onco.cc/api/v1/entities/nct05727904.json